利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.113 秒)

    Stable plurilamellar vesicles
    11.
    发明授权
    Stable plurilamellar vesicles 失效
    稳定的多层囊泡

    公开(公告)号：US5169637A

    公开(公告)日：1992-12-08

    申请号：US679569

    申请日：1991-04-02

    申请人： Robert P. Lenk ,  Michael W. Fountain ,  Andrew S. Janoff ,  Mircea C. Popescu ,  Steven J. Weiss ,  Richard S. Ginsberg ,  Marc J. Ostro ,  Sol M. Gruner

    发明人： Robert P. Lenk ,  Michael W. Fountain ,  Andrew S. Janoff ,  Mircea C. Popescu ,  Steven J. Weiss ,  Richard S. Ginsberg ,  Marc J. Ostro ,  Sol M. Gruner

    IPC分类号： A61K9/127

    CPC分类号： A61K9/127 ,  A61K9/1277

    摘要： A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the emunization of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.

    摘要翻译： 描述了称为稳定多层囊泡（SPLV）的新的和基本上改进的类型的脂质囊泡，以及制备相同的方法和用于鉴定其的X射线衍射方法。 SPLV的特征在于包裹含有一个或多个截留的溶质的水性隔室的脂质双层，每个水分隔室中的这种溶质的浓度基本上等于用于制备SPLV的溶质的排出。 SPLV的双层基本上是非压缩的。 SPLV在储存期间是稳定的，并且可以在体内用于化合物的持续释放和疾病的治疗。

    Stable plurilamellar vesicles
    13.
    发明授权
    Stable plurilamellar vesicles 失效
    稳定的多层囊泡

    公开(公告)号：US5030453A

    公开(公告)日：1991-07-09

    申请号：US660573

    申请日：1984-10-12

    申请人： Robert P. Lenk ,  Michael W. Fountain ,  Andrew S. Janoff ,  Mircea C. Popescu ,  Steven J. Weiss ,  Richard S. Ginsberg ,  Marc J. Ostro ,  Sol M. Gruner

    发明人： Robert P. Lenk ,  Michael W. Fountain ,  Andrew S. Janoff ,  Mircea C. Popescu ,  Steven J. Weiss ,  Richard S. Ginsberg ,  Marc J. Ostro ,  Sol M. Gruner

    IPC分类号： A61K9/127

    CPC分类号： A61K9/1277 ,  A61K9/127

    摘要： A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the concentration of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.

    摘要翻译： 描述了称为稳定多层囊泡（SPLV）的新的和基本上改进的类型的脂质囊泡，以及制备相同的方法和用于鉴定其的X射线衍射方法。 SPLV的特征在于包围含有一个或多个截留的溶质的水性隔室的脂质双层，每个水分隔室中的这种溶质的浓度基本上等于用于制备SPLV的溶质的浓度。 SPLV的双层基本上是非压缩的。 SPLV在储存期间是稳定的，并且可以在体内用于化合物的持续释放和疾病的治疗。

    Liposome-gel compositions
    15.
    发明授权
    Liposome-gel compositions 失效
    脂质体凝胶组合物

    公开(公告)号：US4708861A

    公开(公告)日：1987-11-24

    申请号：US695887

    申请日：1985-01-31

    申请人： Mircea C. Popescu ,  Alan L. Weiner ,  Sharon S. Carpenter-Green

    发明人： Mircea C. Popescu ,  Alan L. Weiner ,  Sharon S. Carpenter-Green

    IPC分类号： A61K9/127 ,  A61K43/00 ,  A61K49/00

    CPC分类号： A61K9/127 ,  Y10T428/2984

    摘要： Compositions and methods for maintaining reservoirs of bioactive agents by sequestering the reservoir in a gel matrix are described. In particular, liposomes containing an entrapped bioactive agent are sequestered in a gel matrix. The resulting liposome-gel compositions may be used in vivo or in vitro to provide for sustained release of the bioactive agent. The gel matrix inhibits the dispersion and clearance of the sequestered liposomes without interfering with the ability of the liposomes to release the entrapped bioactive agent. Furthermore, the rate of release of the bioactive agent from the liposome-gel compositions may be varied by altering the composition of the liposomes and/or gels.

    摘要翻译： 描述了通过将凝胶基质中的储层隔离来维持生物活性剂储库的组合物和方法。 特别地，含有截留的生物活性剂的脂质体被螯合在凝胶基质中。 所得的脂质体 - 凝胶组合物可以在体内或体外用于提供生物活性剂的持续释放。 凝胶基质抑制隔离脂质体的分散和清除，而不会干扰脂质体释放截留的生物活性剂的能力。 此外，可以通过改变脂质体和/或凝胶的组成来改变生物活性剂从脂质体 - 凝胶组合物的释放速率。

    Multilamellar coalescence vesicles (MLCV) containing biologically active compounds
    16.
    发明授权
    Multilamellar coalescence vesicles (MLCV) containing biologically active compounds 有权
    含有生物活性化合物的多层聚结囊泡（MLCV）

    公开(公告)号：US06544549B1

    公开(公告)日：2003-04-08

    申请号：US09164350

    申请日：1998-10-01

    申请人： Lawrence T. Boni ,  Michael M. Batenjany ,  Stella Gevantmakher ,  Mircea C. Popescu

    发明人： Lawrence T. Boni ,  Michael M. Batenjany ,  Stella Gevantmakher ,  Mircea C. Popescu

    IPC分类号： A61K9127

    CPC分类号： A61K9/1278 ,  A61K9/1277 ,  Y10S977/907

    摘要： A method for producing multilamellar coalescence vesicles (MLCVs) containing increased amounts of biologically active compound is disclosed. The method involves hydrating at least one powdered lipid in an aqueous buffer at a temperature above the phase transition temperature of the highest melting lipid to form multilamellar vesicles, reducing the size of the multilamellar vesicles to about 20-400 nm to produce small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) or a mixture thereof; and incubating the SUVs, LUVs or mixture thereof with a biologically active compound in an aqueous solution under sufficient conditions to form MLCVs containing the biologically active compound without the use of an organic solvent, a freeze-thawing step or a dehydration step. MLCVs produced by this method contain increased amounts of biologically active compound over prior art liposomes produced with an organic solvent, a freeze-thawing step or a dehydration step and fewer vesicles are substantially free of biologically active compound

    摘要翻译： 公开了一种生产含有增加量的生物活性化合物的多层聚结囊泡（MLCV）的方法。 该方法包括在高于最高熔融脂质的相变温度的温度下在水性缓冲液中水合至少一种粉状脂质以形成多层囊泡，将多层囊泡的尺寸减小到约20-400nm，以产生小的单层囊泡（ SUV）或大单层囊泡（LUV）或其混合物; 以及在足够的条件下在水溶液中将SUV，LUV或其混合物与生物活性化合物一起孵育以形成含有生物活性化合物的MLCV，而不使用有机溶剂，冻融步骤或脱水步骤。 通过该方法制备的MLCV含有比现有技术的有机溶剂脂质体增加量的生物活性化合物，冻融步骤或脱水步骤，较少的囊泡基本上不含生物活性化合物